Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Matthew J. Maurer, Jeffrey H. Schwartz, Balarama Gundapaneni, Perry Elliott, Giampaolo Merlini, Márcia Waddington‐Cruz, Arnt V. Kristen, Martha Grogan, Ronald Witteles, Thibaud Damy, Brian Drachman, Sanjiv J. Shah, Mazen Hanna, Daniel P. Judge, Alexandra I. Barsdorf, Peter M. Huber, Terrell A. Patterson, Steve Riley, Jennifer Schumacher, Michelle Stewart, Marla B. Sultan, Claudio Rapezzi

New England Journal of Medicine, 2018

Columbia University, Pfizer (United States), Syneos Health (United States), St Bartholomew's Hospital, University College London, University of Pavia, Heidelberg University, Mayo Clinic in Arizona, Stanford University, Amyloidosis Foundation, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire Henri-Mondor, Inserm, University of Pennsylvania Health System, Penn Presbyterian Medical Center, Northwestern University, Cleveland Clinic, Medical University of South Carolina, University of Bologna

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2616

Citations

View on Google Scholar

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Abstract

Journal Details

Join JournalsHub

Welcome Back